CN105008369B - 人类免疫缺陷病毒复制抑制剂 - Google Patents

人类免疫缺陷病毒复制抑制剂 Download PDF

Info

Publication number
CN105008369B
CN105008369B CN201480014236.9A CN201480014236A CN105008369B CN 105008369 B CN105008369 B CN 105008369B CN 201480014236 A CN201480014236 A CN 201480014236A CN 105008369 B CN105008369 B CN 105008369B
Authority
CN
China
Prior art keywords
tert
butoxy
acetic acid
oxo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480014236.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105008369A (zh
Inventor
B.N.奈杜
M.佩特尔
S.丹里
Z.B.郑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN105008369A publication Critical patent/CN105008369A/zh
Application granted granted Critical
Publication of CN105008369B publication Critical patent/CN105008369B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480014236.9A 2013-03-14 2014-03-07 人类免疫缺陷病毒复制抑制剂 Expired - Fee Related CN105008369B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781315P 2013-03-14 2013-03-14
US61/781315 2013-03-14
PCT/US2014/021867 WO2014159076A1 (en) 2013-03-14 2014-03-07 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
CN105008369A CN105008369A (zh) 2015-10-28
CN105008369B true CN105008369B (zh) 2017-07-11

Family

ID=50439486

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480014236.9A Expired - Fee Related CN105008369B (zh) 2013-03-14 2014-03-07 人类免疫缺陷病毒复制抑制剂

Country Status (5)

Country Link
US (1) US9540393B2 (https=)
EP (1) EP2970297A1 (https=)
JP (1) JP6268656B2 (https=)
CN (1) CN105008369B (https=)
WO (1) WO2014159076A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152211A1 (en) 2014-02-12 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) * 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
CN116005285B (zh) * 2022-12-26 2025-03-25 广东蒙泰高新纤维股份有限公司 一种抗紫外回收餐盒聚丙烯纤维的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111653A2 (en) * 2008-03-05 2009-09-11 Biocryst Pharmaceuticals, Inc. Antiviral therapeutic agents
CN102036996A (zh) * 2008-03-19 2011-04-27 百时美施贵宝公司 作为hiv整合酶抑制剂的桥接杂环
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014028384A1 (en) * 2012-08-16 2014-02-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
KR20090047450A (ko) 2006-08-04 2009-05-12 메르츠 파마 게엠베하 운트 코. 카가아 치환된 피라졸로피리미딘, 이의 제조 방법 및 의약품으로서의 이의 용도
AU2008323561B2 (en) 2007-11-15 2013-07-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5269087B2 (ja) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
EP2215298B1 (en) 2007-11-23 2014-03-26 Koninklijke Philips N.V. Compartment
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG10201408512RA (en) 2009-12-23 2015-02-27 Univ Leuven Kath Novel antiviral compounds
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
KR20130124291A (ko) 2010-07-02 2013-11-13 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
WO2012066442A1 (en) 2010-11-15 2012-05-24 Pfizer Limited Inhibitors of hiv replication
AU2012257513B2 (en) * 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
US8791108B2 (en) * 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111653A2 (en) * 2008-03-05 2009-09-11 Biocryst Pharmaceuticals, Inc. Antiviral therapeutic agents
CN102036996A (zh) * 2008-03-19 2011-04-27 百时美施贵宝公司 作为hiv整合酶抑制剂的桥接杂环
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014028384A1 (en) * 2012-08-16 2014-02-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIV进入抑制剂的研究进展;张浩圆，等;《中国生物工程杂志》;20111231;第31卷(第5期);第113-120页 *
抗HIV药物研究进展及发展趋势;王鹏，等;《海峡药学》;20081231;第20卷(第1期);第1-5页 *

Also Published As

Publication number Publication date
JP2016512501A (ja) 2016-04-28
EP2970297A1 (en) 2016-01-20
US20160039844A1 (en) 2016-02-11
WO2014159076A1 (en) 2014-10-02
US9540393B2 (en) 2017-01-10
JP6268656B2 (ja) 2018-01-31
CN105008369A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
CN105189511B (zh) 人免疫缺陷病毒复制的抑制剂
EP3478683B1 (en) Diazepinone derivatives and their use in the treatment of hepatitis b infections
AU2017286890B2 (en) Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
CN105189503B (zh) 人免疫缺陷病毒复制的抑制剂
ES2610708T3 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
AU2018305614B2 (en) Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
EP2814490B1 (en) Inhibitors of human immunodeficiency virus replication
EP2118109B1 (en) Compounds for the treatment of hepatitis c
EP2209789B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN105189510B (zh) 人免疫缺陷病毒复制的抑制剂
CN116670143A (zh) 囊性纤维化跨膜传导调控因子的调节剂
CN105008369B (zh) 人类免疫缺陷病毒复制抑制剂
US9273067B2 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
TW201416363A (zh) Ｃ型肝炎病毒抑制劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170711

Termination date: 20190307